Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Exelixis, Inc.    EXEL

EXELIXIS, INC. (EXEL)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/10/2018 07/11/2018 07/12/2018 07/13/2018 07/16/2018 Date
21.35(c) 21.61(c) 21.92(c) 21.86(c) 21.07(c) Last
5 768 171 3 499 529 4 038 107 2 756 497 3 801 441 Volume
+1.14% +1.22% +1.43% -0.27% -3.61% Change
More quotes
Financials (USD)
Sales 2018 720 M
EBIT 2018 272 M
Net income 2018 271 M
Finance 2018 813 M
Yield 2018 -
Sales 2019 902 M
EBIT 2019 358 M
Net income 2019 355 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 24,70
P/E ratio 2019 19,56
Capi. / Sales2018 7,88x
Capi. / Sales2019 7,19x
Capitalization 6 489 M
More Financials
Company
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer.It offers products under the brands of Cometriq, Cabometyx, and Cotellic.The company was founded by Corey S. Goodman and Stelios B.... 
More about the company
Surperformance© ratings of Exelixis, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on EXELIXIS, INC.
07/12EXELIXIS : to Be Added to the S&P MidCap 400 Index
AQ
07/09EXELIXIS : Announces CELESTIAL Phase 3 Pivotal Trial Results Published in the Ne..
AQ
07/04EXELIXIS : Announces CELESTIAL Phase 3 Pivotal Trial Results Published in The Ne..
BU
07/02EXELIXIS : to Be Added to the S&P MidCap 400 Index
AQ
07/02EXELIXIS : At $21.52 Exelixis, Inc. (EXEL) Forms Double Bottom
AQ
06/27EXELIXIS : to Be Added to the S&P MidCap 400 Index
BU
06/26GE, Lam Research and Lennar climb while Akamai stumbles
AQ
06/26TODAY'S RESEARCH REPORTS ON TRENDING : Exelixis and Zafgen
AC
06/21EXELIXIS : Study Findings from Exelixis, Inc. Provide New Insights into Kidney C..
AQ
06/21EXELIXIS : Studies Conducted at Exelixis, Inc. on Pharmacokinetics Recently Repo..
AQ
More news
Sector news : Bio Therapeutic Drugs
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on EXELIXIS, INC. 
EXELIXIS - 2013
A downturn could form
SELL
More Strategies
Latest Tweets
07/13$EXEL Inc. Cabozantinib is approved in three indications but needs further e.. 
07/10$EXEL D1 long setup base breakout play 
07/08Exelixis $EXEL Stock Rating Lowered by ValuEngine  
07/06Head-To-Head Survey: Exelixis $EXEL & PRA Health Sciences $PRAH
1
07/05Exelixis Announces CELESTIAL Phase 3 Pivotal Trial Results Published in The N.. 
More tweets
Qtime:132
News from SeekingAlpha
07/16The Smart Way To Find Undervalued Stocks 
07/123 THINGS IN BIOTECH, JULY 12 : Immunotherapy Brawl, And A Creeper In The Weeds 
07/07YOUR DAILY PHARMA SCOOP : Exelixis Publishes Positive Data, Stellar Trial Succee.. 
07/05Results from late-stage study of Exelixis' Cabometyx in liver cancer publishe.. 
06/26PREMARKET GAINERS AS OF 9 : 05 am (06/26/2018) 
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | EXEL | US30161Q1040 | 4-Traders
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 33,2 $
Spread / Average Target 52%
EPS Revisions
Managers
NameTitle
Michael M. Morrissey President, Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Christopher J. Senner Chief Financial & Accounting Officer, Executive VP
Gisela M. Schwab Chief Medical Officer & President-Medical Affairs
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Sector and Competitors
1st jan.Capitalization (M$)
EXELIXIS, INC.-30.69%6 489
GILEAD SCIENCES8.01%100 614
VERTEX PHARMACEUTICALS20.45%45 997
REGENERON PHARMACEUTICALS-2.21%38 951
GENMAB5.49%10 457
NEUROCRINE BIOSCIENCES, INC.32.61%9 250